Menu

+ SHARE

Eshoo, Barton Introduce Pathway for Biosimilars Act

March 14th, 2008

March 13, 2008

Washington, D.C. – Today, Rep. Anna G. Eshoo (D-California) introduced the Pathway for Biosimilars Act, legislation to create a regulatory pathway for FDA approval of “biosimilars” or “follow-on” biologics with Rep. Joe Barton (R-Texas), Ranking Member of the House Energy & Commerce Committee.

“This legislation will establish a regulatory pathway for biosimilars that will promote competition and lower prices, and protect patient safety, drug efficacy and sound science,” said Rep. Eshoo. “The most exciting developments in modern medical science are occurring in the field of biotechnology, and this legislation will ensure that the amazing cures and treatments biotech delivers today will continue and more patients will have access to these revolutionary therapies.”

Many of the original patents in the biotechnology industry are beginning to expire and several patient groups, biotech companies, and healthcare providers have called on Congress to provide a regulatory pathway for follow-on biologics or biosimilars to be approved by the FDA. The Pathway for Biologics Act provides an abbreviated pathway for approval of biosimilars based in part on the safety and efficacy record of an innovative reference product.

The Pathway for Biologics Act permits the FDA to make a determination as to whether the biosimilar is interchangeable with the reference product, and gives the FDA the flexibility to determine what clinical testing – if any – is required for approval. To promote continued innovation in biotechnology, the legislation provides 12 years of data exclusivity to allow innovators to market their products and recoup their investments in research and development. Finally, to prevent uncertainty and delays over patent litigation, the bill establishes a process for resolution of patent disputes prior to the time biosimilar products are eligible to come onto the market.

“This legislation will protect patients, promote innovation, and prevent unnecessary litigation,” said Eshoo. “I’m pleased to have my colleague Rep. Joe Barton as a partner on this important bipartisan effort and we will work together to enact this legislation before the end of this Congress.”

# # #

Read Rep. Eshoo’s introduction of the Pathway for Biosimilars Act here

Read a summary of H.R. 5629, the Pathway for Biosimilars Act here

Read the text of the bill here

Get Updates from Anna

How Can Anna Help You?

In this section, you will find information on the many ways my office can help you and your family. Below is a list of the issues we commonly address. If you cannot find what you're looking for, please either email me or call my Palo Alto District Office and we will do our best to answer any questions you may have.

Anna's Voting Record

View All

Thomas Bill Search

@RepAnnaEshoo

Broadband providers should not be allowed to block websites they may not like, or discriminate against services and… https://t.co/iOEUyXgnnA

February 7th, 2019

@RepAnnaEshoo

Broadband providers should not be allowed to block websites they may not like, or discriminate against services and… https://t.co/iOEUyXgnnA

@RepAnnaEshoo

Broadband providers should not be allowed to block websites they may not like, or discriminate against services and… https://t.co/iOEUyXgnnA

@RepAnnaEshoo

For too long unreasonable forces have prevented serious consideration of virtually any gun legislation in Congress… https://t.co/lZVAQX24XM

February 6th, 2019

@RepAnnaEshoo

For too long unreasonable forces have prevented serious consideration of virtually any gun legislation in Congress… https://t.co/lZVAQX24XM

@RepAnnaEshoo

For too long unreasonable forces have prevented serious consideration of virtually any gun legislation in Congress… https://t.co/lZVAQX24XM

Text SizeA A A